Award of up to $31 million supports development of osteoarthritis treatment
Researchers, including Lori Setton in McKelvey Engineering, aim to create treatment that promotes tissue regeneration, restores joints
Osteoarthritis, a degenerative joint disease, limits the mobility of 32 million people nationwide, many to the point of significant disability. Affected individuals face limited options, as there are no drugs to cure or substantially lessen the disease, and invasive joint replacement is often the only option when it reaches its later stages.
With the goal of creating therapeutics that can help the body prevent or reverse the progression of osteoarthritis without surgical intervention, researchers at Washington University in St. Louis have received an award of up to $31 million from the Advanced Research Projects Agency for Health (ARPA-H). The agency, within the U.S. Department of Health and Human Services, was established in 2022 to improve the government’s ability to accelerate biomedical and health solutions.
A multidisciplinary team led by scientists at the School of Medicine and including faculty from the McKelvey School of Engineering, and Arts & Sciences aims to develop a single-injection treatment that promotes tissue regeneration and restores joints. The award falls under ARPA-H’s NITRO program, for Novel Innovations for Tissue Regeneration in Osteoarthritis.
Read the full story here.
Click on the topics below for more stories in those areas
Back to NewsFaculty in this story
